MAPT and Cerebral ischemia: Degradation and aggregation of MAP2 and Tau hyperphosphorylation are biomarkers for the progression of ischemic damage (Pettigrew et al., 1996), and are supported by some studies showing immunoreactivity of tau in neurons and glia from thalamus, hippocampus and cerebral cortex in brain slices from people who suffered an ischemic event (Uchihara et al., 1995, 2000; Irving et al., 1996) and also in experimental cerebral ischemia models (Geddes et al., 1994; Dewar and Dawson, 1995; Irving et al., 1996).